Spinraza (nusinersen) treatment helped school-age children with SMA be more independent in tasks involving their arms and ...

This has resulted in major motor and survival benefits.5–7 In the past 7 years, disease-modifying therapies including nusinersen (Spinraza; Biogen, USA), onasemnogene abeparvovec (Zolgensma; Novartis, ...

NICE is unable to make a recommendation on omaveloxolone (Skyclarys) for treating Friedreich’s ataxia in people 16 years and over. This is because Biogen withdrew its evidence submission.

Alongside Skyclarys, Biogen’s rare disease business is headed by spinal muscular atrophy treatment Spinraza (nusinersen). Spinraza generated global Q1 2025 sales of $423.9m, up from $341.3m in ...

Biogen Inc. (BIIB) came out with quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.67 per share a year ago. These ...

Spinal muscular atrophy treatment Spinraza (nusinersen) became Biogen’s best-selling drug in Q1 2025. Image credit: Shutterstock/ Tada Images. Biogen has unveiled Q1 2025 revenues above estimates, ...

The company’s rare disease business, led by Skyclarys (omaveloxolone) and Spinraza (nusinersen), delivered a 33% sales increase to $563 million. In contrast, revenue from Biogen’s multiple sclerosis ...

- On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the first quarter ended March 31, 2025. “With an encouraging start to ...

Gilead isn't the only one—the last few years have included similar settlements from the likes of both Pfizer and Biogen.